Podcast - CDMO Capabilities in Challenging Times

Podcast - CDMO Capabilities in Challenging Times

Information

When a pharmaceutical sponsor company decides it wishes to outsource vital functions such as manufacturing, drug development, and formulation, they are looking for several key qualities in a service provider. 

CDMOs need to provide flexibility, collaboration and innovation, as well as the ability to continuously evolve their offering. 

In this CPhI Worldwide podcast with Stefano Togni, Business Development Director at Indena, we explore how CDMOs are adapting to changing market conditions amid these challenging times. 

Indena SpAIndena is very well known as a leading API contract developer and supplier. Funded in Italy in 1921, the company is privately owned and serving the global markets with its 4 manufacturing plants. The technological offer covers APIs of botanical, fermentation and synthetic origin, with a unique expertise for HPAPIs. Capitalizing on its twenty year experience in handling HPAPIs development and manufacturing at large industrial scale, an additional new kilolab (LK2), designed to handle the production of highly toxic substances endowed with an OEL of 20 ng/m3 (including toxins for ADCs), was opened in 2018; given the market success, it is now undergoing capacity doubling . Additionally, Indena has opened in 2019 a pilot pharmaceutical plant featuring all the technologies available at Indena, to support clinical APIs and small commercial supplies, with a high degree of flexibility. Besides, a multipurpose fermentation suite (20 thousand liter capacity) is available with the possibility to handle toxic compounds. As far as Spray Drying is concerned, Indena has available two SDs working from organic solvents in the presence of excipients (a PSD2 was installed in 2019). A new smaller scale SD for HIPOs (with OEL ? 1 ?g/m3) will be available in 2021. Indena is continuously investing in its CDMO offer.

Log in

See all the content and easy-to-use features by logging in or registering!